IL3Rα antibody conjugates and uses thereof

A pharmaceutical composition comprising an antibody conjugate that binds to the human IL-3 receptor alpha chain in an amount effective to reduce cancer cells in an animal with myeloid leukemia, wherein the antibody conjugate comprises the VH and VL domains of the 26292, 32701, 32716 or 32703 antibodies, and wherein the antibody is conjugated to a cytotoxic agent.

A pharmaceutical composition comprising an antibody conjugate that binds to the human IL3-receptor alpha chain in an amount effective to reduce cancer stem cells in an animal with myeloid leukemia, wherein the antibody conjugate comprises the VH and VL domains of the 26292, 32701, 32716 or 32703 antibodies, and wherein the antibody is conjugated to a cytotoxic agent.

A method of treating acute myeloid leukemia comprising administering to a patient diagnosed with acute myeloid leukemia an antibody that binds to the human IL-3 receptor alpha chain, in an amount sufficient to inhibit the proliferation of acute myeloid leukemia cells in the patient, wherein the antibody is conjugated to a cytotoxic agent, and wherein the antibody comprises the VH and VL domains of the 26292, 32701, 32716 or 32703 antibodies.

A method of treating acute myeloid leukemia, comprising:

• (a) administering to a patient diagnosed with acute myeloid leukemia an antibody or a fragment thereof that binds to the human IL-3 receptor alpha chain, in an amount sufficient to reduce acute myeloid leukemia stem cells in the patient, wherein the antibody is conjugated to a cytotoxic agent, and
• (b) detecting the acute myeloid leukemia stem cells,
• wherein the antibody comprises the VH and VL domains of the 26292, 32701, 32716 or 32703 antibodies.

A method of treating hematologic cancer comprising administering to a patient diagnosed with hematologic cancer an antibody that binds to the human IL-3 receptor alpha chain, in an amount sufficient to inhibit the proliferation of hematologic cancer cells in the patient, wherein the antibody is conjugated to a cytotoxic agent, and wherein the antibody comprises the VH and VL domains of the 26292, 32701, 32716 or 32703 antibodies.

A method of treating hematologic cancer, comprising:

• (a) administering to a patient diagnosed with hematologic cancer an antibody or a fragment thereof that binds to the human IL-3 receptor alpha chain, in an amount sufficient to reduce hematologic cancer stem cells in the patient, wherein the antibody is conjugated to a cytotoxic agent, and
• (b) detecting the hematologic cancer stem cells,
• wherein the antibody comprises the VH and VL domains of the 26292, 32701, 32716 or 32703 antibodies.